Matthew R. Smith, Judith Manola, Donald S. Kaufman, Daniel George, William K. Oh, Elisabetta Mueller, Susan Slovin, Bruce Spiegelman, Eric Small and Philip W. Kantoff Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy Cancer 101
Version of Record online: 13 AUG 2004 | DOI: 10.1002/cncr.20493
Rosiglitazone, a peroxisome proliferator-activated receptor γ agonist that has been approved to treat type 2 diabetes, did not increase prostate-specific antigen (PSA) doubling time or prolong the time to disease progression more than placebo in men with rising PSA levels who had undergone radical prostatectomy and/or received radiation therapy.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field